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ABSTRACT
Introduction: Psoriatic arthritis (PsA) is a
chronic, inflammatory arthritis that affects an
estimated 30% of patients with psoriasis. PsA is
underdiagnosed in primary care and dermatol-
ogy clinics due to a variety of reasons, including
failure of healthcare providers to ask about
symptoms, overlap of symptoms and signs with
other rheumatologic conditions, and lack of a
specific diagnostic test. A delay in PsA diagnosis
and treatment, even as short as 6 months, can
lead to decreased quality of life, increased joint
damage, and worse long-term physical func-
tion. In this study, we sought to identify the
clinical and genetic factors that help discrimi-
nate patients with PsA from those with cuta-
neous psoriasis only.
Methods: We analyzed a cohort of 974 psoriasis
patients at an academic medical center, of
whom 175 had confirmed PsA, and performed
univariate, multivariate, and predictive model-
ing to determine factors associated with PsA.
Results: The univariate analysis revealed signifi-
cant positive associations of PsA with age, nail
involvement, scalp involvement, skin fold
involvement, elbow/knee involvement, psoriasis
severity, plaque subtype, erythrodermic subtype,
hypertension, type 2 diabetes, and coronary
artery disease, and a significant negative associa-
tion of PsA with the human leukocyte antigen
(HLA)-C*06:02 allele. In the multivariate analysis,
nail involvement, type 2 diabetes, and pustular
psoriasis remained significantly associated with
PsA, while HLA-C*06:02 positivity remained pro-
tective. There was a trend towards an association
of PsA with older age, younger age of psoriasis
onset, and skin fold involvement, while there was
protective trend for smoking. A predictive model
including both clinical and genetic factors
showed reasonable discriminative ability between
psoriasis and PsA, with an area under the curve of
0.87 for a receiver operating characteristic curve.
Conclusion: This study identified a number of
clinical and genetic features that could help
stratify patients who are at higher risk for
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having PsA and for whom rheumatology referral
may be beneficial.
Keywords: Association; Demographics;
Genetics; Prediction; Psoriasis; Psoriatic
arthritis; Risk
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic, inflammatory
arthritis that affects an estimated 30% of patients
with psoriasis [1]. Patients with PsA have a higher
prevalence of cardio-metabolic comorbidities [2].
They are also at risk for permanent deformity and
disability, decreased quality of life (QoL), reduced
work productivity, increased risk of death, and
higher healthcare utilization [3]. Currently, more
than 50% of patients with PsA are untreated or
undertreated with only topical medications [4].
Delays in PsA treatment, even as short as
6 months, can lead to decreased QoL, increased
joint damage, and worse long-term physical
function [5]. Early recognition of PsA is therefore
crucial to reducing joint destruction and
improving long-term disease outcomes.
While studies have found associations
between PsA, smoking [6–8], obesity [9], genetic
risk factors [10], and various psoriasis subtypes
[11, 12], these studies looked at a limited set of
variables and the results are sometimes contra-
dictory or have yet to be confirmed by addi-
tional research. Furthermore, to our knowledge,
no studies have developed models to predict the
risk or presence if PsA.
The aim of this study was to assess the asso-
ciation of PsA with a multidimensional panel of
clinical, demographic, environmental, and
genetic factors and to develop clinically useful
statistical models that help identify patients
who are likely to have PsA.
METHODS
Patient Population
Cross-sectional survey data were collected from
974 psoriasis patients seen at the University of
California, San Francisco Department of
Dermatology between 2006 and 2017. Subjects
included both treatment-naı¨ve patients and
those on topical, systemic, and phototherapy
treatments for psoriasis. Study subjects com-
pleted a detailed survey, providing information
on demographic characteristics, personal and
family medical history, smoking history, age of
onset, history of previous and current psoriasis
treatments, and clinical features (subtype,
affected areas, severity [defined by percentage
body surface area covered], aggravating factors,
presence of joint symptoms) of psoriasis. The
diagnosis of psoriasis was confirmed by a board-
certified dermatologist who had examined the
patient prior to enrollment. A confirmed diag-
nosis of PsA was defined as a diagnosis of PsA
made by a rheumatologist or dermatologist
with patient report of joint symptoms. Possible
PsA was defined as the absence of an official
diagnosis by a physician in the presence of
current symptoms of joint swelling, pain, and
stiffness in one or more joints. The absence of
PsA was defined as a lack of clinical signs and
symptoms as assessed by the physician, no
patient-reported prior diagnosis of PsA by a
physician, and no patient reported symptoms of
possible PsA. For this study, only subjects with
confirmed PsA were classified as having PsA and
compared to subjects without PsA, while those
with possible PsA were omitted from the anal-
ysis. This study was approved by the University
of California, San Francisco’s institutional
review board and informed consent was
obtained from all subjects enrolled in the study.
Genetic Analysis
DNA was extracted from whole blood or saliva
samples donated by the study participants using
the Qiagen DNeasy kit (QIAGEN, Hilden, Ger-
many) or the Oragene prepIT DNA extraction
kit (DNA Genotek, Ottawa, ON, Canada),
respectively. The DNA samples were genotyped
using the Affymetix UK Biobank Array (Affy-
metix Inc., Santa Clara, CA, USA). The copy
number of human leukocyte antigen (HLA)-
C*06:02 and HLA-B*27 alleles were imputed
from array data using HLA*IMP2, which has an
accuracy of C 95% for HLA-C and HLA-B [13].
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Statistical Analyses
All statistical analyses were performed in R
(version 3.3.2; R Foundation for Statistical
Computing, Vienna, Austria). The initial pool of
variables was selected based on evidence of
possible associations with PsA in the literature
and biological plausibility.
Association Models
To avoid over-fitting, the model was limited to
one predictor for every ten events, with an
event defined as the presence of PsA. Using this
heuristic, we determined that our model could
include a maximum of 17 predictor variables.
For genetic variables we used a binary definition
of positivity for the HLA-C*06:02 and HLA-B*27
alleles (patient did not have the HLA allele vs.
the patient had at least one copy of the allele).
Initial univariate analyses were conducted using
Chi-squared tests or Fisher’s exact tests for cat-
egorical variables and two-tailed t tests for
continuous variables. An a priori threshold of a
p value of\0.25 was used to select variables for
inclusion in the subsequent multivariable
logistic regression model. Demographic char-
acteristics (age, age of onset, gender, body mass
index [BMI]) were forced into the model to
control for potential confounders. A backward
elimination method based on the p value of the
Wald test statistic was used to reduce the model
to 17 predictor variables. Sensitivity analyses
were conducted using alternative pre-defined
p value thresholds of 0.15 and 0.05 to determine
whether a more stringent barrier to inclusion
would alter the results. We also used an alter-
native definition of severity as a four-level
ordinal variable.
Prediction Models
We constructed two multivariable logistic
regression models to predict the presence of
PsA. Model 1 included only factors that are
known to predate the onset of PsA, such as age
of psoriasis onset, gender, family history of
psoriasis, and the copy number of HLA-C*06:02
and HLA-B27 alleles. The full data set was used
to assess the diagnostic ability of model 1 and
construct a receiver operating characteristic
curve.
For model 2, which included variables that
were associated with PsA and not necessarily
predating PsA onset, the dataset was split into a
training set (25%) and independent test set used
for validation (75%). The training set was used
to develop model 2, while the test set was used
to determine the internal validity of the model
and construct the ROC curves. Stepwise regres-
sion based on the Akaike information criterion
was used to build model 2 from a pool of all
investigated variables. The variable, HLA-
C*06:02 positivity, was forced into model 2 as
previous studies had suggested that this allele
has a significant protective effect against the
development of PsA [14–16]. The concordance
statistic (c-index), defined as the area under the
ROC curve was used to assess the predictive
accuracy of the two predictive logistic regres-
sion models.
The presence of multicollinearity was asses-
sed using the variance inflation factor. The
generalized additive models approach was used
to test the assumption that the continuous
variables (age and age of onset) were linearly
related to the logit in the logistic regression
model [17]. The Hosmer–Lemeshow test was
used to assess the models’ goodness of fit.
RESULTS
Description of Study Population
The prevalence of confirmed PsA in our cohort
was 18.0% (n = 175), while the prevalence of
subjects without confirmed PsA was 51%
(n = 497). The average age of our study popu-
lation was 44.6 years; 55% of our cohort was
male and 44.9% were female. The average BMI
was 27.1 kg/m2, a value which is considered to
indicate clinically overweight and slightly
above the national average [18]. Our study
population drew from the Bay area of California
and was predominantly Caucasian, Asian, and
Hispanic/Latino. Characteristics of the training
and internal validation cohorts are provided in
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Electronic Supplementary Material (ESM)
Table S1.
Univariate Associations with PsA
We first analyzed a number of demographic,
clinical, and genetic variables on a univariate
basis for association with PsA (Table 1). We
found significant positive associations for age
(p = 0.024), scalp psoriasis (p = 0.004), elbow/
knee psoriasis (p = 0.040), nail involvement
(p = 8.2 9 10-08), skin fold involvement
(p = 0.005), plaque subtype (p = 0.01), erythro-
dermic subtype (p = 0.014), severe psoriasis
(p = 2.39 9 10-5), hypertension (p = 0.003),
type 2 diabetes (p = 0.024), and coronary artery
disease (p = 0.045). We found a significant
negative association for the HLA-C*06:02 allele
(p = 0.003).
Multivariate Association Model
Next, we built a multivariate association model
using a backward elimination method (Table 2).
Among the demographic characteristics inclu-
ded in the final multivariable logistic regression
model, only the age of psoriasis onset showed a
trend towards a higher odds of having PsA
(p = 0.050). For every 1 year increase in the age
of onset, the odds of having PsA decreased by
3%.
Clinical features, such as lesion location and
psoriasis subtype, were also associated with
increased odds of PsA. Patients who had nail
psoriasis had a 3.01-fold higher odds of having
PsA (95% confidence interval [CI] 1.39–6.66;
p = 0.006) than did individuals without nail
involvement. Those with pustular psoriasis had
a 6.11-fold odds of having PsA (95% CI
1.40–36.41; p = 0.022) than did those who did
not.
In terms of co-morbidities, subjects who had
type 2 diabetes had a significant 5.27-fold
increase in the odds of having PsA (95% CI
1.17–36.8; p = 0.037) that was independent of
current BMI and hypertension status.
Genetically, individuals who were positive
(heterozygous or homozygous) for the HLA-
C*06:02 allele had a 67% reduction in the odds
of having PsA relative to patients who lacked
HLA- C*06:02. There was no significant differ-
ence in the odds of PsA for patients who had the
HLA-B*27 allele.
A number of other variables showed a trend
toward association with PsA in the multivariate
model, but these were not statistically signifi-
cant. These included intertriginous psoriasis,
plaque psoriasis, severe psoriasis, and smoking
(Table 2).
Sensitivity Analysis
Reducing the p value for entry into the model to
0.15 or 0.05 did not significantly change the
parameter estimates or p values. The only vari-
able appreciably affected was pustular psoriasis
status, which had a p value of 0.064 in the
univariate analyses and therefore did not make
the cutoff for inclusion in the model that used
an entry criteria of p\0.05. The results of these
sensitivity analyses (ESM Tables S2, S3, S4)
suggest that our association model is fairly
robust. Moreover, we conducted an additional
sensitivity analysis examining whether forcing
the variable of ethnicity/race (Caucasian, Asian,
and Hispanic/Latino, Other) into the models
altered the results and found that the none of
our findings was significantly
altered (ESM Appendix).
Multivariate Predictive Models
The association model assessed the relationship
between PsA and the most significant factors
found on univariate analysis while controlling
for demographic variables; in comparison, the
predictive models evaluated how well a set of
variables predict the presence of PsA. The results
of the multivariable logistic regression model
using only factors that are known to predate PsA
onset (model 1) are shown in Table 3. Only the
HLA-C*06:02 allele was found to be a statisti-
cally significant predictor of PsA status
(p = 0.001). Patients with one or more copies of
the HLA-C*06:02 allele had a 55% reduction in
the odds of having PsA compared to individuals
who did not have any copies of the HLA-
C*06:02 allele. The c-index was 0.615 (Fig. 1,
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Table 1 Univariate analysis of demographic, clinical, and genetics features associated with psoriatic arthritis
Demographic, clinical, and
genetics features
Patient group p valuea OR [95% CI]b
PsA No PsA
Mean age (years) 48.46 45.06 0.024* 0.002 [0.0003–0.004]
Age of psoriasis onset (years) 26.07 28.09 0.193 - 0.001 [- 0.003 to
0.0006]
Gender, n female/total (% female) 85/175 (48.6%) 208/495
(42.0%)
0.158 1.30 [0.92–1.84]
BMI 27.84 26.63 0.094e 0.006 [- 0.001 to 0.014]
Family history of psoriasis, n
yes/total
(% yes)
98/175 (56.0%) 254/488
(52.0%)
0.418 1.17 [0.83–1.66]
HLA-C*06:02 positivity 38/175 (21.7%) 156/497
(31.4%)
0.003** 0.53 [0.35–0.80]
HLA-B*27 positivity 11/175 (6.3%) 28/497 (5.6%) 1.000 1.05 [0.51–2.16]
Smoking, n yes/total (% yes) 6/175 (3.4%) 30/472 (6.4%) 0.211 0.52 [0.21–1.28]
Clinical factors
Scalp involvement 153/175
(87.4%)
382/497
(76.9%)
0.004** 2.09 [1.28–3.43]
Ear involvement 114/175
(65.1%)
283/497
(56.9%)
0.078e 1.40 [0.98–2.01]
Elbow/knee involvement 145/175
(82.9%)
371/497
(74.6%)
0.040* 1.62 [1.04–2.53]
Arm/leg involvement 152/175
(86.9%)
423/497
(85.1%)
0.660 1.16 [0.70–1.91]
Trunk involvement 133/175
(76.0%)
346/497
(69.6%)
0.132 1.38 [0.93–2.05]
Face involvement 79/175 (45.1%) 206/497
(41.4%)
0.446 1.16 [0.82–1.64]
Genital involvement 63/175 (36.0%) 142/497
(28.6%)
0.082e 1.41 [0.98–2.03]
Nail involvement 101/175
(57.7%)
170/497
(34.2%)
8.21 9 10-08*** 2.63 [1.85–3.74]
Palm involvement 40/175 (22.9%) 103/497
(20.7%)
0.627 1.13 [0.75–1.71]
Sole involvement 39/175 (22.3%) 83/497 (16.7%) 0.125 1.43 [0.93–2.19]
Skin fold involvement 79/175 (45.1%) 162/497
(32.6%)
0.005** 1.69 [1.19–2.40]
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Table 1 continued
Demographic, clinical, and
genetics features
Patient group p valuea OR [95% CI]b
PsA No PsA
Gluteal cleft involvement 27/175 (15.4%) 84/497 (16.9%) 0.739 0.90 [0.56–1.44]
Plaque subtype 157/175
(89.7%)
402/497
(80.9%)
0.010* 2.06 [1.21–3.52]
Guttate subtype 52/175 (29.7%) 137/497
(27.6%)
0.656 1.11 [0.76–1.62]
Pustular subtype 11/175 (6.3%) 14/497 (2.8%) 0.064e 2.31 [0.93–5.60]
Erythrodermic subtype 13/175 (7.4%) 14/497 (2.8%) 0.014* 2.77 [1.27–6.01]
Palmoplantar subtype 13/175 (7.4%) 22/497 (4.4%) 0.181 1.73 [0.85–3.52]
Inverse subtype 17/175 (9.7%) 29/497 (5.8%) 0.116 1.74 [0.93–3.24]
Severity – – 0.0005 –
Mild 6/169 (3.6%) 30/497 (6.0%) 0.262 0.55 [0.23–1.35]
Mild–moderate 23/175 (13.1%) 107/497
(21.5%)
0.021* 0.55 [0.34–0.90]
Moderate–severe 54/175 (30.9%) 185/497
(37.2%)
0.155 0.75 [0.52–1.09]
Severec 88/175 (50.3%) 159/497
(32.0%)
2.39 9 10-5*** 2.15 [1.51–3.05]
Comorbidities
Hypertension 61/175 (34.9%) 115/497
(23.1%)
0.003** 1.78 [1.22–2.58]
Diabetes, type 2 18/175 (10.3%) 25/497 (5.0%) 0.024* 2.16 [1.15–4.07]
Hypercholesterolemiad 38/175 (21.7%) 119/497
(23.9%)
0.6202 0.88 [0.58–1.33]
Hypertriglyceridemiad 16/175 (9.1%) 31/497 (6.2%) 0.261 1.51 [0.81–2.84]
Coronary artery disease 12/175 (6.8%) 15/497 (3.0%) 0.045* 2.37 [1.08–5.16]
Stroked 4/175 (2.3%) 7/497 (1.4%) 0.660 1.64 [0.35–6.53]
Values for variables are presented as the number of patients out of the total number of patients in that group, with the
percentage of these patients given in parenthesis, with the exception of mean age and age of psoriasis onset
PsA Psoriatic arthritis, OR odds ratio, CI confidence interval, BMI body mass index, HLA human leukocyte antigen
*, **, ***Results are statistically significant at *p\ 0.05 , **p value\ 0.01, or highly significant at ***p\ 0.001
a p values derived from t-tests or Wilcoxon rank sum tests for continuous variables and Chi squared or Fisher’s exact tests
for categorical variables
b ORs for continuous variables (age, age of onset, BMI) are per unit increase
c P value for severity included in model as severe or not severe (binary)
d Variables with p[ 0.25
e Indicates a trend towards statistical significance (p value\ 0.1)
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suggesting that this limited model was only
slightly better than random prediction (c-index
of 0.500).
The results of model 2, derived from stepwise
regression and using independent training and
validation datasets are shown in Table 4. The
c-index for model 2 in the training and test sets
were 0.820 and 0.874, respectively (Fig. 2),
which are significantly higher than that for
model 1. Age of psoriasis onset, nail involve-
ment, type 2 diabetes, and hypertriglyceridemia
were all significant predictors of PsA in the
derivation cohort. The Hosmer–Lemeshow test
was not significant for any of the logistic
regression models (model 2: p = 0.978), sug-
gesting that the predicted and observed values
were well calibrated with one another.
DISCUSSION
Our multifactorial analysis of demographic,
clinical, environmental, and genetic risk factors
of PsA revealed new characteristics associated
with PsA and demonstrate a novel predictive
model that can help distinguish between those
who have PsA and those who do not. For
example, in one previous study the HLA-
Table 2 Multivariable logistic regression model of psoriatic arthritis
Variablea Odds ratio [95% CI]b p value
Intercept 0.05 [0.00–0.53] 0.015*
Nail involvement 3.01 [1.39–6.66] 0.006**
HLA-C*06:02 positivity 0.33 [0.13–0.77] 0.013*
Diabetes, type 2 5.27 [1.21–24.5] 0.029*
Pustular subtype 6.11 [1.17–36.8] 0.037*
Age of psoriasis onset 0.97 [0.94–1.00] 0.050c
Smoking 0.29 [0.06–1.01] 0.076c
Skin fold involvement 2.09 [0.91–4.89] 0.085c
Age 1.03 [1.00–1.06] 0.091c
Severe psoriasis 1.92 [0.88–4.21] 0.101
Soles involvement 0.44 [0.15–1.15] 0.107
Plaque subtype 2.63 [0.86–9.57] 0.109
Ears involvement 0.54 [0.22–1.29] 0.166
Elbows/knees involvement 1.88 [0.73–5.24] 0.202
Hypertension 0.53 [0.18–1.44] 0.231
Inverse subtype 2.08 [0.51–8.20] 0.296
Gender 1.22 [0.54–2.77] 0.631
BMI 0.99 [0.93–1.05] 0.703
A backward stepwise elimination procedure was used with a threshold of p\ 0.25 for inclusion of variables in the initial
model
*, **Results are statistically significant at *p\ 0.05 or **p value\ 0.01
a Variables listed in order of p value
b ORs for continuous variables (age, age of onset, BMI) are per unit increase
c p value indicates a trend towards statistical significance (p\ 0.1)
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C*06:02 allele was associated with a tenfold
increase in the risk of developing psoriasis [19],
but the results of other studies suggest that the
HLA-C*06:02 allele may be protective against
the development of PsA. More specifically, in a
cohort of 480 patients with PsA, Ho and col-
leagues showed that those with both the HLA-
C*06:02 and HLA-DRB1*07 alleles had
significantly fewer damaged and involved joints
than PsA patients who did not carry either allele
[10]. Furthermore, Winchester and colleagues
found that the frequency of the HLA-C*06:02
allele was lower in patients with psoriatic
arthritis than in patients with only cutaneous
psoriasis. In particular, Haroon and colleagues
found that the HLA-C*06:02 allele was nega-
tively associated with asymmetrical sacroiliitis.
In our psoriasis cohort, which included patients
with and without PsA, we found that positivity
for the HLA-C*06:02 allele was negatively asso-
ciated with PsA, although it should be noted
that the frequency of the HLA-C*06:02 allele in
both patients with PsA (21.7%) and those with
only psoriasis (31.4%) was still higher than that
in the general population.
Our study also identifies a new heightened
association of cardio-metabolic disease with PsA
as compared to psoriasis without PsA. In the
univariate association analysis, the presence of
hypertension, coronary artery disease, or type 2
diabetes was significantly associated with risk of
PsA among those with psoriasis. Moreover, type
2 diabetes was strongly associated with PsA and
was a significant predictor of PsA status in
model 2. These results are consistent with a
previous study by Coto-Segura and colleagues
who have shown that PsA increases the risk of
type 2 diabetes by 2.1 fold [20]. Interestingly,
these authors found that the treatment of dia-
betes with glucagon-like peptide 1 (GLP-1)
Table 3 Results of a predictive multivariable logistic regression model for presence of psoriatic arthritis that includes only
factors predating the onset of psoriatic arthritis (model 1)
Variable Odds ratio (95% CI)a p value
Intercept 0.55 [0.32–0.92] 0.024*
Age of psoriasis onset 0.99 [0.98–1.00] 0.065c
Genderb 1.24 [0.83–1.84] 0.295
HLA-C*06:02 positivity 0.45 [0.29–0.70] 0.0005***
HLA-B*27 positivity 0.96 [0.43–1.99] 0.908
Family history of psoriasis 1.24 [0.83–1.87] 0.291
*, **, ***Results are statistically significant at *p\ 0.05, **p value\ 0.01, or highly significant at ***p\ 0.001
a ORs for continuous variables (age, age of onset, BMI) are per unit increase
b Odds ratio for females relative to the reference group of males
c Indicates a trend towards statistical significance (p\ 0.1)
Fig. 1 Receiver operating characteristic (ROC) curve with
area under the curve for model 1
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analogues improved psoriasis symptoms in
patients with both diabetes and psoriasis.
Moreover, the authors of a prospective study
conducted in the UK for 4 years involving 8124
adults with psoriasis and 76,599 adults without
psoriasis found that psoriasis was a risk factor
for incident diabetes [21]. Taken together, these
results suggest a possible mechanistic link
between PsA endocrine derangements in dia-
betes. While our study did not find a link
between PsA and BMI or obesity, our survey
data only included current BMI values and not
the BMI values at age 18 years that Arabshahi-
Soltani and colleagues [9] found to be associated
with PsA. It is possible that only childhood
obesity and not obesity in later life is associated
with PsA. In fact, PsA seems to be positively
associated with a younger age of onset in our
cohort as well as in other studies [9, 22], sug-
gesting that the clinical course in a patient’s
childhood may set the stage for PsA in later life.
Interestingly, hypertriglyceridemia was nega-
tively associated with PsA in predictive model 2.
High triglyceride levels may be a marker of
treatment with systemic medications, such as
retinoids [23], methotrexate [24], and tumor
necrosis factor-alpha inhibitors [25–27]; these
medications have been associated with
Table 4 Results of model 2, a multivariable logistic regression model for presence of psoriatic arthritis developed by stepwise
regression from an initial pool of all demographic, clinical, environmental, and genetic factors
Variable Odds ratio (95% CI) p value
Model intercept 0.11 [0.01–0.87] 0.045*
Demographic characteristics
Age of psoriasis onset 0.96 [0.92–0.99] 0.017*
Gendera 2.56 [0.93–7.40] 0.072b
Heritable factors
HLA-C*06:02 positivity 0.60 [0.20–1.64] 0.327
Lesion location
Ear involvement 0.35 [0.10–1.06] 0.067b
Nail involvement 3.92 [1.5–10.8] 0.006**
Comorbidities
Cardiovascular disease 15.48 [0.84–610] 0.084b
Diabetes, type 2 9.91 [1.35–82.4] 0.025*
Hypertriglyceridemia 0.03 [0.00–0.48] 0.035*
Subtype
Plaque subtype 4.25 [0.94–26.4] 0.082b
Inverse subtype 5.26 [1.01–23.0] 0.051b
Pustular subtype 4.77 [0.57–47.4] 0.157
Severity
Severe psoriasis 2.03 [0.77–5.44] 0.154
*, **Results are statistically significant at *p\ 0.05 or **p value\ 0.01
a OR for females relative to the reference group of males
b Indicates a trend towards statistical significance (p\ 0.1)
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increased triglyceride levels and may be used to
treat or delay the onset of PsA.
Certain clinical features also seem to be
important predictors of PsA status. For example,
nail psoriasis is seen in both our study and those
of others [9, 12] to be associated with PsA.
‘‘Localized’’ pustular psoriasis has also been
associated with PsA in a Korean psoriasis cohort
studied by Choi and colleagues, although their
study methods did not specify details on the
covariates used [22]. Our models demonstrate
an association between pustular psoriasis and
PsA. The association between PsA and a more
extensive form of pustular psoriasis is supported
by the study of David and colleagues who
described four cases of generalized pustular
psoriasis occurring with systemic amyloidosis,
PsA, and nephrotic syndrome [28]. Overall,
more severe and extensive psoriasis has been
positively linked to PsA [9, 12, 22] and is a sig-
nificant predictor of PsA in model 2.
Some results of our study do differ from
those reported in the literature. For example,
while Wilson et al. described an association
between PsA and inverse psoriasis [12], this was
not seen in our cohort. However, involvement
of the skin folds did trend towards a higher odds
of having PsA. It is possible that the rarity of
inverse psoriasis in our cohort (7.8% overall;
9.7% in PsA-positive subjects and 5.8% in PsA-
negative subjects) may have limited our power
to identify associations with PsA status. Wilson
et al. [12] also reported a link between scalp
psoriasis and PsA [12]. In our study, scalp pso-
riasis was significantly different in the univari-
ate Chi-squared analysis, but it was not
significantly associated with PsA in the multi-
variate logistic regression analysis nor was it a
significant predictor of PsA status in model 2.
This discrepancy may be due, in part, to differ-
ences in the statistical models used. Also, while
the multivariable Cox proportional hazards
models used by Wilson et al. [12] adjusted only
for age, sex, and calendar year, the logistic
regression models used in our study controlled
for numerous other clinical and genetic factors.
Thus, it is possible that there was no significant
association between our models because they
controlled for additional confounders that may
have driven the relationship between scalp
psoriasis and PsA in the analysis performed by
Wilson et al. [12].
Fig. 2 ROC curves with area under the curve for model 2 in the training cohort (a) and test cohort (b)
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It is important to note that our study is limited
by the retrospective and cross-sectional nature of
our data, which prevented us from distinguishing
the directionality of the relationship between PsA
and the risk factors explored in our models. Fur-
thermore, the cross-sectional data also prevented
us from estimating the future risk of PsA,
although our models can be used to help clini-
cians in stratifying patients who are more likely to
have PsA and those who are not. Finally, the lack
of precise characterization of joint involvement
hampered full interpretation of study.
CONCLUSIONS
In this study we evaluated the association of PsA
with a wide variety of risk factors and developed
predictive models that can help clinicians make
earlier diagnoses of PsA and prevent the debili-
tating long-term sequelae of the disease. These
models demonstrate the predictive value of HLA
alleles in combination with clinical and demo-
graphic factors to identify ‘‘high suspicion’’
patients who may be candidates for additional
work-up. Further prospective studies are needed
to understand how these risk factors contribute
to the development of PsA and whether they
can be used to predict future disease onset.
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